Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2023

Bouffet Eric, Geoerger Birgit, Moertel Christopher, Whitlock James A, Aerts Isabelle, Hargrave Darren, Osterloh Lisa, Tan Eugene, Choi Jeea, Russo Mark, Fox Elizabeth

Abstract excerpt

PURPOSE: BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600-mutant LGG; other cohorts will be reported elsewhere. METHODS: This is a four-part, phase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Recurrence, Local

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36375115
DOI: 10.1200/JCO.22.01000
PMCID: PMC9870224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.PMID 36375115Read ↗

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.Semantic proximity Read ↗

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Semantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudySemantic proximity Read ↗

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.Semantic proximity Read ↗

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid TumorsSemantic proximity Read ↗

Dabrafenib-trametinib is effective in paediatric high-grade glioma.Semantic proximity Read ↗

Targeted Therapy Win in BRAF-Mutant Gliomas.Semantic proximity Read ↗

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.